{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:03:40Z","timestamp":1789707820115,"version":"4.0.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Eravacycline is a novel fluorocycline with potent activity against carbapenem-resistant Enterobacterales (CRE). However, comparative validation of gradient diffusion (MIC Test Strip, MTS) and disk diffusion (DD) against reference broth microdilution (BMD) specifically in CRE isolates remains limited, particularly under region-specific breakpoint systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study evaluated the performance of the MTS and DD against BMD for eravacycline susceptibility testing in 358 CRE clinical isolates (174 carbapenem-resistant\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      , CRKP and 144 carbapenem-resistant\n                      <jats:italic>Escherichia coli<\/jats:italic>\n                      , CREC), using both U.S. Food and Drug Administration (FDA) and Expert Committee of the National Health Commission on Antimicrobial Susceptibility Testing and Standard Research (ChinaCAST) breakpoints. Categorical agreement (CA), essential agreement (EA), major error (ME), and very major error (VME) were assessed according to CLSI M52 criteria, and Bland-Altman analysis was performed for quantitative agreement between MTS and BMD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      BMD showed MIC\n                      <jats:sub>50<\/jats:sub>\n                      \/MIC\n                      <jats:sub>90<\/jats:sub>\n                      of 0.25\/1 mg\/L, with overall susceptibility rate of 81.2% by FDA breakpoints. For MTS, overall CA and EA were 92.8% and 92.5%, but VME was 33.8% under FDA breakpoints, concentrated in CRKP (35.5%). Under ChinaCAST breakpoints, CRKP CA increased to 94.8%, yet VME decreased to 18.2% and ME increased to 4.3%. For DD, overall CA was 89.9% with VME of 32.3%; only CREC under FDA breakpoints achieved acceptable CA (97.9%) and error rates, whereas ChinaCAST breakpoints yielded unacceptable CA (77.0-77.8%) and elevated ME (22.4-24.5%) for both species.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Eravacycline retains potent\n                      <jats:italic>in vitro<\/jats:italic>\n                      activity against CRE. MTS is suitable for routine testing of CREC, and DD is reliable for CREC under FDA breakpoints. For CRKP, neither method satisfied CLSI M52 criteria, and reference BMD remains indispensable.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1932734","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:30:59Z","timestamp":1789705859000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of eravacycline susceptibility testing by MIC test strip and disk diffusion against broth microdilution in carbapenem-resistant Enterobacterales"],"prefix":"10.3389","volume":"16","author":[{"given":"Kangyu","family":"Wang","sequence":"first","affiliation":[{"name":"Tumor Research and Treatment Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]},{"name":"Postdoctoral Research Station, The Affiliated Taian City Central Hospital of Qingdao University","place":["Taian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjing","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Liaocheng Second People\u2019s Hospital","place":["Liaocheng, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingchao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Affiliated Taian City Central Hospital of Qingdao University","place":["Taian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunzhong","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Binzhou People\u2019s Hospital","place":["Binzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Affiliated Taian City Central Hospital of Qingdao University","place":["Taian, China"]},{"name":"Shandong Provincial Key Medical and Health Laboratory of Anti-Drug Resistant Drug Research, The Affiliated Taian City Central Hospital of Qingdao University","place":["Taian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Affiliated Taian City Central Hospital of Qingdao University","place":["Taian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Affiliated Taian City Central Hospital of Qingdao University","place":["Taian, China"]},{"name":"Shandong Provincial Key Medical and Health Laboratory of Anti-Drug Resistant Drug Research, The Affiliated Taian City Central Hospital of Qingdao University","place":["Taian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1128\/AAC.04809-14","article-title":"Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City","volume":"59","author":"Abdallah","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/phar.2366","article-title":"Evaluation of eravacycline: a novel fluorocycline","volume":"40","author":"Alosaimy","year":"2020","journal-title":"Pharmacotherapy"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01650-22","article-title":"Multicenter clinical evaluation of ETEST eravacycline for susceptibility testing of Enterobacteriaceae and Enterococci","volume":"61","author":"Blanchard","year":"2023","journal-title":"J. Clin. Microbiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.04873-22","article-title":"In vitro activities of aztreonam-avibactam, eravacycline, cefoselis, and other comparators against clinical Enterobacterales isolates: a multicenter study in Chin","volume":"11","author":"Chen","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"B6","doi-asserted-by":"publisher","article-title":"Antimicrobial resistance profile of clinical isolates in hospitals across China: report from the CHINET Antimicrobial Resistance Surveillance Program 2025","year":"2026","DOI":"10.1186\/s44280-025-00092-0"},{"key":"B7","article-title":"Verification of commercial microbial identification and antimicrobial susceptibility testing systems","year":"2015"},{"key":"B8","article-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 12th ed","year":"2024"},{"key":"B9","article-title":"Performance standards for antimicrobial disk susceptibility tests, 14th ed","year":"2024"},{"key":"B10","article-title":"Performance standards for antimicrobial susceptibility testing, 36th ed","year":"2026"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens14121214","article-title":"Resistance of Gram-negative bacteria to eravacycline: a systematic review of data from in vitro studies","volume":"14","author":"Falagas","year":"2025","journal-title":"Pathogens"},{"key":"B12","article-title":"Response to STMA request for changes to the document titled, Guidance for Industry and FDA Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems","year":"2015"},{"key":"B13","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jgar.2023.04.017","article-title":"In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020","volume":"33","author":"Hawser","year":"2023","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1177\/1060028019850173","article-title":"Eravacycline: the tetracyclines strike back","volume":"53","author":"Heaney","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1093\/jac\/dkae220","article-title":"Establishment of epidemiological cut-off values for eravacycline, against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Acinetobacter baumannii and Staphylococcus aureus","volume":"79","author":"Jing","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1093\/jac\/dkae426","article-title":"Comparative evaluation of eravacycline susceptibility testing methods in 587 clinical carbapenem-resistant Acinetobacter baumannii isolates: broth microdilution, MIC test strip and disc diffusion","volume":"80","author":"Liu","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2022.127249","article-title":"Global spread of carbapenem-resistant Enterobacteriaceae: epidemiological features, resistance mechanisms, detection and therapy","volume":"266","author":"Ma","year":"2023","journal-title":"Microbiol. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0140-6736(24)02081-6","article-title":"Multidrug-resistant Gram-negative bacterial infections","volume":"405","author":"Macesic","year":"2025","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01699-19","article-title":"In vitro activity of eravacycline against Gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3760\/cma.j.cn114452-20250211-00074","article-title":"Specifications for antimicrobial susceptibility testing of eravacycline, (2025)","volume":"48","year":"2025","journal-title":"Zhonghua Jianyan Yixue Zazhi"},{"key":"B21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"B22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S1473-3099(19)30210-5","article-title":"Carbapenem-resistant Enterobacteriaceae: global action required","volume":"19","author":"Perez","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"dkag248","DOI":"10.1093\/jac\/dkag248","article-title":"Comparative evaluation of disc diffusion, Liofilchem\u2122 MTS strips, Etest\u00ae Biom\u00e9rieux with broth microdilution for eravacylin susceptibility testing","volume":"81","author":"Ronsin","year":"2026","journal-title":"J. Antimicrob. Chemother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S1473-3099(25)00118-5","article-title":"The WHO bacterial priority pathogens list 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance","volume":"25","author":"Sati","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg."},{"key":"B26","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens","volume":"57","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin. Infect. Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/cid\/ciae110","article-title":"The natural history of carbapenemase-producing Enterobacterales: progression from carriage of various carbapenemases to bloodstream infection","volume":"79","author":"Temkin","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"B29","unstructured":"Breakpoint Tables for Interpretation of Mics and Zone Diameters V 16.0\n          \n          2026"},{"key":"B30","article-title":"Eravacycline-injection products","year":"2022"},{"key":"B31","doi-asserted-by":"publisher","first-page":"dkaf502","DOI":"10.1093\/jac\/dkaf502","article-title":"Comparison of disk diffusion, MIC test strip and broth microdilution for eravacycline susceptibility testing of 422 Staphylococcus aureus isolates using ChinaCAST breakpoints","volume":"81","author":"Wang","year":"2026","journal-title":"J. Antimicrob. Chemother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.cmi.2025.04.014","article-title":"Comparison of disk diffusion, MIC test strip and broth microdilution methods for eravacycline susceptibility testing","volume":"31","author":"Yang","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"key":"B33","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/ja.2016.73","article-title":"In vitro susceptibility of beta-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline","volume":"69","author":"Zhang","year":"2016","journal-title":"J. Antibiot. (Tokyo)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1186\/s12879-019-4093-1","article-title":"In vitro activities of eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China","volume":"19","author":"Zhao","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.2147\/IDR.S396910","article-title":"Antibacterial activity of eravacycline against carbapenem-resistant Gram-negative isolates in China: an in vitro study","volume":"16","author":"Zou","year":"2023","journal-title":"Infect. Drug Resist."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1932734\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:31:08Z","timestamp":1789705868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1932734\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":35,"alternative-id":["10.3389\/fcimb.2026.1932734"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1932734","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1932734"}}